.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, patients with metastatic gastrointestinal lumps that obtained biomarker-matched therapies based on spreading tumor DNA profiling presented a better clinical advantage than those receiving incomparable therapy.